Pancreatic ductal adenocarcinoma: Clinical trials to watch.
Pancreatic cancer treatment is shifting from one-size-fits-all chemotherapy toward precision approaches targeting specific genetic mutations and tumor characteristics.
This review summarizes active and upcoming clinical trials in PDAC, highlighting the transition from uniform chemotherapy to precision strategies guided by RAS mutations, BRCA status, and neoantigen profiles. After decades of stagnation, PDAC is entering a phase of rational drug development with multiple molecular targets under investigation in pivotal studies.
What the study was
- Study design
- Clinical review (trials landscape article)
- Population
- Pancreatic ductal adenocarcinoma patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Med (New York, N.Y.)
Why it surfaced
Landmark review of precision oncology trials entering PDAC—historically the deadliest major cancer—with directly monitoring-worthy trials across novel molecular targets.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.